Advances of hafnium based nanomaterials for cancer theranostics

Jiayi Wang; Jiahua Pan; Yijun Tang; Jingqi Chen; Xiaochen Fei; Wei Xue; Xueliang Liu

doi:10.3389/fchem.2023.1283924

Advances of hafnium based nanomaterials for cancer theranostics

Front Chem. 2023 Nov 24:11:1283924. doi: 10.3389/fchem.2023.1283924. eCollection 2023.

Authors

Jiayi Wang^#¹, Jiahua Pan^#¹, Yijun Tang², Jingqi Chen¹, Xiaochen Fei¹, Wei Xue¹, Xueliang Liu¹

Affiliations

¹ Department of Urology and Institute of Molecular Medicine (IMM), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
² Department of Endocrinology and Metabolism, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

^# Contributed equally.

Abstract

Hafnium-based nanomaterials (Hf-NMs) have attracted the interest of numerous biomedical researchers by their unique properties. Recent years have witnessed significant advancements in the field of Hafnium-based nanomaterials, particularly in the context of cancer diagnosis and treatment. However, research in this area, especially concerning the clinical application of Hafnium-based nanomaterials, has not been thoroughly reviewed. This review will cover: 1) Classification and synthesis of Hafnium-based nanomaterials including Hafnium oxide nanomaterials, Hafnium Metal-Organic Frameworks/nanoscale coordination polymers (MOFs/NCPs); 2) Hafnium-based nanomaterials act as contrast enhancement agent for cancer imaging, and hafnium-based nanomaterials used for diagnosis in cancer liquid biopsy; 3) hafnium-based nanomaterials for cancer therapy, including hafnium-based nanomaterials for radiotherapy, hafnium-based nanomaterials for photodynamic therapy, hafnium-based nanomaterials for various combined therapy; and 4) Translation, toxicity, and safety for Hf-NMs in human and preclinical animal models. More attention will be given to the clinical translation of Hf-NMs in cancer.

Keywords: Hf-based nanomaterials (Hf-NMs); bioimaging; biosafety; cancer therapy; combination therapy.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Shanghai Key Clinical Specialty Construction Project Urology (Renji Hospital), the National Natural Science Foundation of China (82272002, 81901747, 82203069, 82227801), Program of Shanghai Subject Chief Scientist (19XD1402300), Program for Outstanding Medical Academic Leader (2019LJ11), National Natural Science Foundation Promotion Project of Renji Hospital, Shanghai Jiao Tong University School of Medicine (RJTJ22-MS-012), “Clinic Plus” Outstanding Project (nos. 2023ZYB006 and 2021ZYA007) from Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, and Innovative research team of high-level local universities in Shanghai.